As aging mice have been reported to have chronically high levels of mTORC1, as discussed above, the reversal of the suppression of AKT-regulated UPS by mTORC1 may provide a potential target for therapeutic reduction of sarcopenia in aging. The gene discussed is AKT1; the disease is sarcopenia.